Reported side effects of Singulair (montekulast) include aggression, depression, suicidal thoughts and hallucinations, especially among children. In 2020, the FDA updated the drug’s warning label and strengthened it two years later, but physicians are still writing millions of prescriptions.
Twelve million Americans are prescribed the medication, including 1.6 million children. A recent study found that 62.4% of children with asthma who took montekulast reported neuropsychiatric events.
The FDA says it is reviewing adverse events related to Singulair, but in a letter, Ms. James asked the agency to reeducate clinicians about the drug’s potential risks and evaluate whether Singulair, which has been on the market for 25 years, outweigh the side effects.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.